Photo of Anne-Marie A. Wills, MD, MPH

Anne-Marie A. Wills, MD, MPH

617-726-5532

Accepting New Patients

Overview

To make a neuromuscular division appointment, call 617-726-3642.

Departments

Neurology

Clinical Interests
  • ALS (Lou Gehrig's disease)
  • Movement disorders
Medical Education
  • MD, Columbia University College of Physicians and Surgeons
  • MPH, Harvard School of Public Health
  • Residency, Brigham and Women's Hospital
  • Fellowship, Massachusetts General Hospital
Board Certifications
  • Neurology
Foreign Languages
  • Spanish
Locations
  • Boston: Massachusetts General Hospital
Patient Gateway
Yes, learn more
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
Patient Age Group
Adult
Gender
Female

Edit Profile

Biography

Anne-Marie Wills M.D. M.P.H. is a Neurologist specializing in neurodegenerative disease, such as Parkinson's Disease and A.L.S. She received her B.A. from Princeton University, her M.D. from Columbia College Physicians & Surgeons, and her M.P.H. from Harvard School of Public Health. She completed her specialty training in the Partners Neurology residency program, a combined program between Massachusetts General Hospital and Brigham and Women's Hospital. She has been on staff at M.G.H. since 2006.

Dr. Wills' research focuses on environmental risk factors and determinants of neurodegenerative disease progression, including nutrition, caffeine and pesticides. Her multi-center clinical trial of nutrition in ALS (funded by the Muscular Dystrophy Association) showed that a calorically-dense diet was better tolerated and led to fewer adverse events, including deaths, than a standard diet (Wills et al. The Lancet, 2014).  This study was prompted by human and animal data which showed an increase in ALS survival from obesity and weight gain. She is also the M.G.H. Investigator on several Parkinson's Disease clinical trials testing therapeutic interventions in P.D

http://www.massgeneral.org/about/pressrelease.aspx?id=1682

Edit Profile

Research & Publications

Research Summary

Dr. Wills' research focuses on environmental risk factors and determinants of neurodegenerative disease progression, including nutrition, caffeine and pesticides. Her multi-center clinical trial of nutrition in ALS (funded by the Muscular Dystrophy Association) showed that a calorically-dense diet was better tolerated and led to fewer adverse events, including deaths, than a standard diet (Wills et al. The Lancet, 2014).  This study was prompted by human and animal data which showed an increase in ALS survival from obesity and weight gain. She is also the M.G.H. Investigator on several Parkinson's Disease clinical trials testing therapeutic interventions in P.D.

Publications

Wills AM, Cronin S , Slowik A, et al. Meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology. 2009 73(1):16-24.

Paganoni S; Deng J; Jaffa M; Cudkowicz ME; Wills AM. Body Mass Index, not dyslipidemia, is an independent predictor of survival in ALS. Muscle and Nerve. 2011 44(1):20-4

Paganoni S; Zhang M; Quiroz Z?rate A; Jaffa M; Yu H; Cudkowicz ME; Wills AM. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. Journal of Neurology. 2012 259 (9):1923-1928.

Wills AM, Eberly S, Tennis M, et al. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013

Wills AM, Hubbard J, Mackline EA et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial, The Lancet, Online Publication, 28 February 2014

Edit Profile

News & Events

  • Early weight loss in Parkinson disease patients may signify more serious form of disease

    While weight loss is common in Parkinson's patients, results of a study led by an MGH investigator could suggest that weight loss early in the course of the disease signifies a more serious form of the neurodegenerative disorder.

  • High-calorie feeding may slow progression of ALS

    Increasing the number of calories consumed by patients with amyotrophic lateral sclerosis (ALS) may be a relatively simple way of extending their survival. A phase 2 clinical trial led by Massachusetts General Hospital physicians found that ALS patients receiving a high-calorie, high-carbohydrate tube-feeding formula lived longer with fewer adverse events than participants who received a standard formula designed maintain their weight.

  • Mild obesity appears to improve survival in ALS patients

    Patients with amyotrophic lateral sclerosis (ALS) may be an exception to the rule that being overweight is a health hazard. In a retrospective study of over 400 ALS patients, MGH researchers found that those who were mildly obese survived longer than patients who were normal weight, underweight or even overweight.

Contact

Neurology & Stroke Services
15 Parkman Street
Boston MA, 02114-3117
Phone 1: 617-726-5532
Phone 2: 617-724-9234
Fax: 617-726-4101

Edit Profile

Back to Top